BENITIONSClinical Trial Intelligence

Severe Asthma, MepolizumaB and Affect: SAMBA Study

不适用 已完成 NCT04680611

适应症Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression
分期不适用
申办方University Hospital Southampton NHS Foundation Trust
状态已完成
受试者人数120 人
干预(药物)no study intervention. Patients receive standard clinical care
开始日期2021年9月9日
完成日期2025年3月26日
结果公布日2026年7月13日

摘要

This is a real-life pragmatic non-randomised study to explore the impact of mepolizumab on the emotional and affective outcomes of patients with severe eosinophilic asthma and their partners. It will be conducted in two quantitative stages (Phases 1 and 2) with an additional third qualitative component (Phase 3).

Change in Emotional Composition (Using the Geneva Emotions Wheel)

Change to one year after start of treatment · score

Patients With Severe Eosinophilic Asthma Phase 20.9 score
Partners of Patients With Severe Eosinophilic Asthma Phase 20.1 score
Patients With Severe Eosinophilic Asthma Phase 20.7 score
Partners of Patients With Severe Eosinophilic Asthma Phase 20.0 score
Patients With Severe Eosinophilic Asthma Phase 20.0 score
Partners of Patients With Severe Eosinophilic Asthma Phase 20.2 score

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。